塔乌尔苏氧胆酸脂质体通过恢复肠道屏障和肠道微生物群来缓解DSS诱导的性结肠炎
Junke Zhao1, Suqi Hao1, Yan Chen1
1School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Colloids and surfaces. B, Biointerfaces
|February 20, 2024
概括
基于Tauroursodeoxycholic酸 (TUDCA) 的脂质体通过减少炎症和恢复肠道屏障完整性,有效治疗性结肠炎 (UC). 这种新的治疗方法促进了微生物群平衡,并为UC患者提供了有前途的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 纳米医学是一种纳米医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,治疗选择有限.
- 目前的UC疗法专注于炎症,但忽视了粘膜修复和微生物群平衡.
- 需要新的治疗方法来解决UC多方面的病理问题.
研究的目的:
- 开发和评估TUDCA/Emodin脂质体作为一种治疗性结肠炎的新疗法.
- 评估TUDCA/Emodin脂质体在缓解UC症状和恢复肠道平衡中的有效性.
- 研究TUDCA/Emodin脂质体对肠道屏障功能和肠道微生物群的影响.
主要方法:
- 通过用TUDCA替换胆固醇并结合emodin来制备TUDCA/Emodin脂质体.
- 在体外评估脂质体特性,包括颗粒大小,稳定性,细胞毒性,粘液透性和抗炎活性.
- 在UC模型中对TUDCA/Emodin脂质体的体内评估,测量结肠长度,炎症,内分泌网膜应激 (ERS),紧密结合蛋白和肠道微生物群组成.
主要成果:
- 图迪卡/埃莫丁脂质体表现出均的大小,良好的稳定性,低细胞毒性和增强的粘液透性.
- 试验室研究显示了显著的抗炎作用和保护氧化应激.
- 口服TUDCA/Emodin脂质体显著缓解了UC的严重程度,增加了结肠长度,减少了炎症和ERS,恢复了紧结蛋白 (Claudin-1,ZO-1),并促进了肠道微生物群的恢复.
结论:
- 图迪卡/埃莫丁脂质体代表了性结肠炎的新有效治疗方法.
- 这种配方通过减少炎症,修复肠道屏障和重新平衡肠道微生物群来解决UC问题.
- 开发出来的脂质体提供了一个有希望的,易于转化的治疗策略,用于恢复UC的肠道平衡.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Drugs Affecting GI Tract Motility: Other Laxatives
217
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
217
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
486
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
486
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145


